TNF-alpha 44ng/ml R08 exp533 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== TNF-alpha 44ng/ml R08 exp533 ======
==== Mechanism of Action ====
Ligand for TNFR1, induces apoptosis or necrosis
  * **<color #00a2e8>Class / Subclass 1:</color>** Signal Transduction / Other Receptor Agonist




==== Technical Notes ====
<accordion collapsed='true'>
<panel title='Compound References' collapsed='true'>
    * **<color #00a2e8>PubChem Name:</color>** %%N/A%%
    * **<color #00a2e8>Synonyms:</color>** N/A
    * **<color #00a2e8>CAS #:</color>** N/A
    * **<color #00a2e8>PubChem CID:</color>** N/A
    * **<color #00a2e8>IUPAC:</color>** %%N/A%%
    * **<color #00a2e8>INCHI Name:</color>** N/A
    * **<color #00a2e8>INCHI Key:</color>** N/A
    * **<color #00a2e8>Molecular Weight:</color>** 16.9kDa
    * **<color #00a2e8>Canonical SMILES:</color>** N/A
    * **<color #00a2e8>Isomeric SMILES:</color>** N/A
    * **<color #00a2e8>Molecular Formula:</color>** MRKR+KPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN
{{:chemogenomics:structures:chem-0337.svg?nolink}}
</panel>


<panel title='Compound Supplier' collapsed='true'>
    * **<color #00a2e8>Supplier Name:</color>** Cusabio
    * **<color #00a2e8>Catalog #:</color>** CSB-AP002151HU
    * **<color #00a2e8>Lot #:</color>** 03962
</panel>


<panel title='Compound Characterization' collapsed='true'>
Characterization data not available.
</panel>


<panel title='Dose Response Curve' collapsed='true'>
    * **<color #00a2e8>Platform ID:</color>** TNF_alpha
    * **<color #00a2e8>Min:</color>** -13.9154; **<color #00a2e8>Max:</color>** 15.1482
{{:chemogenomics:dose_response:dr_590.png?nolink&500 |}}
\\ 
\\ 
\\ 
\\ 
|< 300px 100px 200px >|
^ IC   ^ Concentration (µM) ^
| IC10  |N/A    |
| IC20  |N/A    |
| IC30  |N/A    |
| IC40  |N/A    |
| IC50  |N/A    |
| IC60  |N/A    |
| IC70  |N/A    |
| IC80  |N/A    |
| IC90  |N/A    |
\\ 
</panel>
</accordion>
==== Screen Summary ====
    * **<color #00a2e8>Round</color>**: 08
    * **<color #00a2e8>Dose</color>**: 44ng/mL
    * **<color #00a2e8>Days of incubation</color>**: 8
    * **<color #00a2e8>Doublings</color>**: 6.6
    * **<color #00a2e8>Numbers of reads</color>**: 14832845


==== Screen Results ====


^Sensitive/Resistant hits (FDR<0.05)^CRANKS^Score Plot^Top 30 Genes^Screen Similarity^Top 30 Sensitive GO terms^Top 30 Resistant GO terms^
|8/0|<color #e85500>[[https://files.tyerslab.com/files/public/chemogenomics/cranks/TNF-alpha_44_ng_per_mL_Round-8_exp533.txt|Scores]]</color>|<button type="primary" size="sm" modal="ScorePlot">View</button>|<button type="primary" size="sm" modal="modal_hits">View</button>|<button type="default" size="sm" modal="modal_screen_similarity">View</button>|<button type="primary" size="sm" modal="modal_go_sensitive">View</button>|<button type="primary" size="sm" modal="modal_go_resistant">View</button>|
<modal id='ScorePlot' size='lg' title='TNF-alpha 44ng/ml R08 exp533'>
{{:chemogenomics:cranks_plots:exp533.png?nolink}}
</modal>


<modal id="modal_hits" size="sm" title="Top 30 S/R Genes">
^Gene^CRANKS Score^FDR^
|[[:human_genes:T:TRAF2|TRAF2]]|-4.62|<0.01|
|[[:human_genes:T:TNFAIP3|TNFAIP3]]|-4.04|<0.01|
|[[:human_genes:R:RNF31|RNF31]]|-3.76|<0.01|
|[[:human_genes:A:ATG9A|ATG9A]]|-3.60|<0.01|
|[[:human_genes:I:IKBKG|IKBKG]]|-3.40|<0.01|
|[[:human_genes:W:WIPI2|WIPI2]]|-3.19|<0.01|
|[[:human_genes:C:CFLAR|CFLAR]]|-2.94|<0.01|
|[[:human_genes:C:C12orf44|C12orf44]]|-2.78|<0.01|
|[[:human_genes:C:CCT2|CCT2]]|-2.74|0.57|
|[[:human_genes:V:VPS25|VPS25]]|-2.67|0.41|
|[[:human_genes:R:RIPK1|RIPK1]]|-2.43|0.06|
|[[:human_genes:Z:ZNF30|ZNF30]]|-2.43|0.06|
|[[:human_genes:C:CNOT2|CNOT2]]|-2.41|0.06|
|[[:human_genes:B:BIRC2|BIRC2]]|-2.32|0.15|
|[[:human_genes:L:LUC7L2|LUC7L2]]|-2.28|0.15|
|[[:human_genes:U:UBE2N|UBE2N]]|-2.28|0.11|
|[[:human_genes:N:NCOA5|NCOA5]]|-2.27|0.15|
|[[:human_genes:Z:ZNF638|ZNF638]]|-2.24|0.14|
|[[:human_genes:D:DUSP11|DUSP11]]|-2.22|0.14|
|[[:human_genes:C:CNOT4|CNOT4]]|-2.20|0.15|
|[[:human_genes:C:C10orf142|C10orf142]]|-2.19|0.22|
|[[:human_genes:M:MAP3K7|MAP3K7]]|-2.15|0.15|
|[[:human_genes:K:KIF6|KIF6]]|-2.14|0.15|
|[[:human_genes:D:DCAF15|DCAF15]]|-2.07|0.32|
|[[:human_genes:H:HOXA5|HOXA5]]|-2.06|0.22|
|[[:human_genes:C:CD1D|CD1D]]|-2.05|0.23|
|[[:human_genes:P:PIK3R3|PIK3R3]]|-1.99|0.30|
|[[:human_genes:C:C2orf88|C2orf88]]|-1.98|0.31|
|[[:human_genes:P:PPHLN1|PPHLN1]]|-1.98|0.41|
|[[:human_genes:F:FRG2B|FRG2B]]|-1.96|0.32|
|[[:human_genes:C:CDC5L|CDC5L]]|1.93|0.61|
|[[:human_genes:S:SUPT6H|SUPT6H]]|1.96|0.68|
|[[:human_genes:T:TRIOBP|TRIOBP]]|1.96|0.60|
|[[:human_genes:A:ANXA5|ANXA5]]|1.97|0.60|
|[[:human_genes:R:RPS27A|RPS27A]]|1.97|0.60|
|[[:human_genes:C:CASP8|CASP8]]|1.98|0.60|
|[[:human_genes:B:BANF1|BANF1]]|1.98|0.71|
|[[:human_genes:A:ATP6V0B|ATP6V0B]]|2.01|0.79|
|[[:human_genes:M:MDM2|MDM2]]|2.01|0.66|
|[[:human_genes:B:BEND3|BEND3]]|2.02|0.60|
|[[:human_genes:Z:ZDHHC3|ZDHHC3]]|2.03|0.61|
|[[:human_genes:R:RPS29|RPS29]]|2.06|0.61|
|[[:human_genes:P:PNO1|PNO1]]|2.06|0.72|
|[[:human_genes:O:OR10X1|OR10X1]]|2.09|0.60|
|[[:human_genes:P:PAK4|PAK4]]|2.10|0.46|
|[[:human_genes:P:POLR1A|POLR1A]]|2.11|0.61|
|[[:human_genes:Z:ZNF431|ZNF431]]|2.11|0.61|
|[[:human_genes:K:KDM6A|KDM6A]]|2.13|0.43|
|[[:human_genes:N:NVL|NVL]]|2.19|0.70|
|[[:human_genes:C:CATSPER3|CATSPER3]]|2.20|0.61|
|[[:human_genes:P:PAFAH1B1|PAFAH1B1]]|2.30|0.72|
|[[:human_genes:C:CRAMP1L|CRAMP1L]]|2.31|0.20|
|[[:human_genes:F:FADD|FADD]]|2.32|0.20|
|[[:human_genes:P:POLE|POLE]]|2.41|0.61|
|[[:human_genes:Y:YTHDC2|YTHDC2]]|2.43|0.20|
|[[:human_genes:T:TSR2|TSR2]]|2.45|0.70|
|[[:human_genes:C:CDC34|CDC34]]|2.50|0.13|
|[[:human_genes:D:DDX3X|DDX3X]]|2.62|0.13|
|[[:human_genes:N:NUP88|NUP88]]|2.65|0.13|
|[[:human_genes:P:PSMA3|PSMA3]]|2.75|0.15|
</modal>


<modal id="modal_screen_similarity" size="lg" title="Correlated Screens">
No correlation data above threshold. (correlation > 0.05)
</modal>


<modal id="modal_go_sensitive" size="lg" title="Top 30 sensitive GO terms">
^GO Term^Fold Change^Genes^
|linear polyubiquitin binding|662.76|RNF31,MAP3K7|
|negative regulation of necroptotic process|132.55|RNF31,RIPK1,BIRC2|
|regulation of necroptotic process|101.96|RNF31,CFLAR,RIPK1,BIRC2|
|programmed necrotic cell death|101.96|TRAF2,ATG9A,RIPK1,BIRC2|
|regulation of programmed necrotic cell death|88.37|RNF31,CFLAR,RIPK1,BIRC2|
|K63-linked polyubiquitin modification-dependent protein binding|82.84|TNFAIP3,RNF31,IKBKG|
|ubiquitin-like protein binding|33.70|TNFAIP3,RNF31,IKBKG,BIRC2,UBE2N,MAP3K7|
|ubiquitin binding|33.47|TNFAIP3,IKBKG,BIRC2,UBE2N,MAP3K7|
|positive regulation of canonical NF-kappaB signal transduction|27.62|TRAF2,RNF31,IKBKG,CFLAR,RIPK1,BIRC2,UBE2N,MAP3K7|
|positive regulation of NF-kappaB transcription factor activity|27.05|TRAF2,RNF31,IKBKG,CFLAR,RIPK1,UBE2N|
|regulation of canonical NF-kappaB signal transduction|23.39|TRAF2,TNFAIP3,RNF31,IKBKG,CFLAR,RIPK1,BIRC2,UBE2N,MAP3K7|
|protein polyubiquitination|19.49|TRAF2,TNFAIP3,RNF31,BIRC2,UBE2N,DCAF15|
|positive regulation of DNA-binding transcription factor activity|16.78|TRAF2,RNF31,IKBKG,CFLAR,RIPK1,UBE2N|
|ubiquitin protein ligase binding|15.57|TRAF2,RNF31,IKBKG,CCT2,RIPK1,UBE2N,MAP3K7|
|ubiquitin-like protein ligase binding|14.68|TRAF2,RNF31,IKBKG,CCT2,RIPK1,UBE2N,MAP3K7|
|regulation of DNA-binding transcription factor activity|12.40|TRAF2,TNFAIP3,RNF31,IKBKG,CFLAR,RIPK1,UBE2N|
|protein ubiquitination|7.76|TRAF2,TNFAIP3,RNF31,BIRC2,UBE2N,CNOT4,DCAF15|
|positive regulation of immune response|7.56|TRAF2,TNFAIP3,RNF31,IKBKG,UBE2N,MAP3K7,CD1D|
|intracellular protein-containing complex|6.82|TRAF2,RNF31,IKBKG,CCT2,CNOT2,UBE2N,CNOT4,MAP3K7,DCAF15|
</modal>
<modal id="modal_go_resistant" size="lg" title="Top 30 resistant GO terms">
^GO Term^Fold Change^Genes^
|TRAIL-activated apoptotic signaling pathway|276.15|FADD,ZDHHC3,CASP8|
|extrinsic apoptotic signaling pathway via death domain receptors|52.60|DDX3X,FADD,ZDHHC3,CASP8|
|ribosome biogenesis|11.35|NUP88,DDX3X,TSR2,NVL,PNO1,UTP3|
</modal>